Therapy of steroid-refractory acute GVHD with CD52
antibody alemtuzumab is effective.
specific antibody CAMPATH could be used as a safety-switch to rapidly terminate cCAR therapy in mouse models.
Alemtuzumab, a monoclonal antibody directed at CD52
. The drug was withdrawn for CLL indication by the producer because of commercial reasons.
Alemtuzumab is a humanized monoclonal IgG1 antibody directed against CD52
, a glycoprotein expressed on mononuclear cells, including T- and Blymphocytes, monocytes, and natural killer cells [136, 137].
Alemtuzumab is a humanised monoclonal antibody targeting the CD52
marker present on B and T lymphocytes, monocytes and macrophages.6 The drug has been employed in the management of numerous diseases that include, inter alia, leukaemia, ocular inflammatory disease and organ transplantation.
.R13 Human Resources for Health: Increasing Access to Qualified Health Workers in Primary Health Care-Based Health Systems.
Alemtuzumab is a monoclonal antibody that recognizes the antigen CD52
, a glycoprotein found in various leukocytes, including lymphocytes, monocytes, macrophages and some dendritic cells.
Treatment options for refractory or recurrent disease include alemtuzumab, a monoclonal antibody to the CD52
protein expressed on the surface of mature T cells and possibly NK cells.
[12.] Hale G (2001 ) The CD52
antigen and development of the CAMPATH antibodies.
Jiwon Oh of the division of neurology at the University of Toronto analyzed outcomes of pregnancies among women who had been treated with alemtuzumab (Lemtrada), an antibody that targets CD52
So Qasim and colleagues used a different pair of TALENs to remove a protein called CD52
from the CAR T cells.